Vγ9Vδ2 T cell

Vγ9Vδ2 T cells are a unique subset of human γδ (gamma delta) T lymphocytes characterized by their expression of the Vγ9 and Vδ2 chains in their T-cell receptor. They are being developed as a form of adoptive cellular immunotherapy for cancer, particularly blood cancers and solid tumors. These cells recognize phosphoantigens in a manner independent of classical HLA presentation, allowing for both autologous and allogeneic use. Their mechanisms include direct tumor cytotoxicity via release of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α), granzymes, perforin-mediated lysis, engagement of apoptosis-inducing receptors (such as NKG2D), antibody-dependent cellular cytotoxicity (ADCC), and cross-presentation to CD8+ αβTCR cells[1][3][7]. Clinical strategies involve ex vivo expansion with agents like zoledronate or synthetic phosphoantigens plus IL-2 before reinfusion into patients[4][6]. Early-phase clinical trials have demonstrated safety and some evidence for efficacy in various cancers including liver cancer, lung cancer, non-small cell lung cancer (NSCLC), multiple myeloma, renal cell carcinoma, gastric cancer, hepatocellular carcinoma, melanoma, ovarian cancer, colon cancer and pancreatic cancer[3][4][5][6]. Research is ongoing to enhance their anti-tumor activity through genetic engineering or combination therapies.

Other names

gamma delta T cellγδ T cellVgamma9Vdelta2 T cellVgamma-9Vdelta2 T cellVgamma 9Vdelta2 T cell